Safety and Efficacy of Emerging Treatments in the Management of Systemic Lupus Erythematosus (SLE)
| Overview / Abstract: |
When measuring outcomes in systemic lupus erythematosus (SLE), it is important for clinicians to monitor disease activity, health-related quality of life, and any irreversible change in the organ system that occurred since the onset of SLE. While there are currently many therapies utilized in treating SLE, such as nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antimalarials, immunosuppressants, chemotherapy, biologics, and adjunctive therapies, there are still unmet needs with a mortality rate at 15 years as well as complications such as lupus nephritis and severe extrarenal disease. However, the future is bright for patients with lupus, as drug development activities are currently unprecedented. In this CMEOCast podcast episode, expert faculty evaluate the safety and efficacy of these emerging therapies. - Learning Objectives - At the end of this CE activity, participants should be able to: |
|
Expiration |
Feb 11, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online, Podcast, Webinar / Webcast / Video |
|
Credits / Hours |
.5 AMA PRA Category 1 Credit(s)™/CEUs/contact hours |
|
Accreditation |
ACCME, ACPE, ABIM MOC, AANP |
|
Presenters / Authors / Faculty |
Allan Gibofsky, MD, JD, MACR, FACP, FCLM Richard A. Furie, MD |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from AstraZeneca Pharmaceuticals |
|
Keywords / Search Terms |
CME Outfitters SLE, lupus, autoimmune, autoimmune disease, systemic lupus erythematosus, NSAIDs, biologics, biosimilars, immunosuppression, rheumatic disease, rheumatologist, rheum, rheumatology, meded, med ed, free CME, free CE, free, online Free CE CME |
|